Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
30 hedge funds and large institutions have $137M invested in Achilles Therapeutics in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
50% more funds holding
Funds holding: 20 → 30 (+10)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more capital invested
Capital invested by funds: $137M → $137M (+$371K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.03M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$1.96M |
| 3 |
BlackRock
New York
|
+$1.29M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$342K |
| 5 |
Renaissance Technologies
New York
|
+$155K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$12M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.51M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.89M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$779K |
| 5 |
Millennium Management
New York
|
-$721K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $6K | +$7.17K | +1,185 | New |
|
|
CSS
27
Cubist Systematic Strategies
Stamford,
Connecticut
| $5K | -$5.3K | -875 | -46% |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | – | – | – |
|
29
Rockefeller Capital Management
New York
| $1K | – | – | – |
|
|
BC
30
Boxer Capital
San Diego,
California
| – | -$12M | -1,536,016 | Closed |
|
|
FCM
31
Farallon Capital Management
San Francisco,
California
| – | -$3.51M | -450,000 | Closed |
|
|
SFM
32
Sphera Funds Management
Tel Aviv,
Israel
| – | -$1.89M | -242,500 | Closed |
|
|
AAA
33
Affinity Asset Advisors
New York
| – | -$779K | -100,000 | Closed |
|
34
Alyeska Investment Group
Chicago,
Illinois
| – | -$239K | -30,730 | Closed |
|
ACHL Hedge Fund Activity: Q4 2021 in Review
30 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q4 2021, worth a combined $137M — up 0.27% from $137M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ACHL positions and 5 closed out — a net gain of 10 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $3.03M. The largest seller was Boxer Capital, exiting entirely with an estimated $12M sold.
- 30 institutional investors held Achilles Therapeutics (ACHL) as of Q4 2021, up from 20 in Q3 2021.
- Funds reported $137M of Achilles Therapeutics stock for Q4 2021, up 0.27% quarter-over-quarter.
- 15 funds opened new Achilles Therapeutics positions in Q4 2021 and 5 closed out, a net change of +10 holders.
- The largest Achilles Therapeutics buyer in Q4 2021 was Point72 Asset Management, an estimated $3.03M added.
- The largest Achilles Therapeutics seller in Q4 2021 was Boxer Capital, an estimated $12M sold.
Based on aggregated 13F filings for Q4 2021.